JGH:肝细胞癌——手术切除与TACE孰优?

2014-01-14 MedSci MedSci原创

韩国成钧馆大学医学院的Moon Seok Choi医生和他的同事们对手术切除肝巨大肿瘤和肝动脉化疗栓塞的远期疗效进行了对比,并对与生存期有关的预后因素进行了评估。自2000年至2009年,有84位患者进行了手术切除,267位患者行肝动脉化疗栓塞。研究者们收集了患者的年龄、性别、肝病病因、是否存在肝硬化和肝功能分级,以及肿瘤大小、数目、范围和血管侵蚀情况的数据信息。主要评价项目是总生存期。其他评

韩国成钧馆大学医学院的Moon Seok Choi医生和他的同事们对手术切除肝巨大肿瘤和肝动脉化疗栓塞的远期疗效进行了对比,并对与生存期有关的预后因素进行了评估。

自2000年至2009年,有84位患者进行了手术切除,267位患者行肝动脉化疗栓塞。研究者们收集了患者的年龄、性别、肝病病因、是否存在肝硬化和肝功能分级,以及肿瘤大小、数目、范围和血管侵蚀情况的数据信息。

主要评价项目是总生存期。其他评价项目还包括总生存期的预后因素。该评价项目主要是通过分数匹配的队列的单变量和多变量分析得出的。该队列有76个年龄、性别、肝病病因、肝功能分级、肿瘤数量、血管侵蚀情况、肿瘤范围与试验组匹配的患者组成。

进行外科手术的患者在前两年内每3个月复查一次,之后每6个月复查一次。复查时进行肝功能测试、血清甲胎蛋白水平测试和肝动态CT来监测肿瘤有无复发。

那些进行肝动脉化疗栓塞的患者在第一个月时进行两次连续的监测,然后每个治疗周期之后的1个月在门诊复查。复查时他们进行类似电池的试验来判断肿瘤分期。如果肝动态CT发现肿瘤后,需要再次进行肝动脉化疗栓塞。



Figure 1. Kaplan-Meier survival curves showing overall survival rates in 351 patients with huge hepatocellular carcinoma after surgery (n=84) and TACE (n=267). Surgery group showed higher 1-, 3-, and 5-year survival rates than TACE group (73.8%, 54.8%, and 39.8% vs. 37.8%, 16.3%, and 9.7%, respectively; P<0.001). 

巨大肝细胞癌手术切除后患者的1年总生存率为69.7%,2年总生存率为58.6%,3年总生存率为51.7%。而肝动脉化疗栓塞后患者的1年总生存率为40.2%,2年总生存率为33.9%,3年总生存率为18.5%。


Figure 2. Kaplan-Meier survival curves showing overall survival rates in propensity score matched-cohort (76 matched pairs) with huge hepatocellular carcinoma after surgery and TACE. Surgery group showed higher 1-, 2-, and 3-year survival rates than TACE group (69.7%, 58.6%, and 51.7% vs. 40.2%, 33.9%, and 18.5%, respectively; P<0.001). 

经多变量分析发现,与生存期有关的因素包括:白蛋白(风险比为0.54, 95% CI 0.34-0.85, P=0.008)和外科手术(风险比为 0.44, 95% CI 0.28-0.70, P=0.001)。

对生存期不利的因素包括:男性(风险比为 1.90, 95% CI 1.01-3.58, P=0.048)和腹水(风险比为 1.77, 95% CI 1.02-3.08, P=0.044)。

   

Figure 3. Kaplan-Meier survival curves showing overall survival rates cirrhosis after surgery and TACE in propensity score matched-cohort (76 matched pairs) according to the presence of cirrhosis: a) in non-cirrhotic patients and b) in cirrhotic patients. 

两组患者的住院死亡率没有明显区别(P=0.14)。进行外科手术的患者中有2人在住院期间死于肝衰竭,而肝动脉化疗栓塞的患者中仅1人死于碘油诱发的急性肺损伤。

肿瘤直径大于等于10cm的患者较肿瘤较小的患者的生存期短。

作者们警示,尽管外科手术后1年、3年、5年患者的生存率较高,但是非手术治疗组患者肝硬化、门静脉或肝静脉侵蚀的发生率较低。患者选择治疗方式的不同可能对结果有一定影响,这使这一研究的价值受到一定的限制。 他们也注意到,这一研究是一个回顾性研究,患者的数量较少,且研究只关注了血管侵蚀的情况,而没有对比血管侵蚀的范围,这些都限制了这一研究的价值。

MedSci评论:这个研究最大特色在于采用了倾向匹配得分方法,纠正了两种的基线差异。否则如果不纠正这种差异,会带来大量的偏倚。因为能手术的患者,肿瘤侵袭范围,肿瘤结节的数量,以及肿瘤的位置可能都较好。而TACE的患者可能状况更差,因此,很难进行比较。采用倾向匹配得分,修正这些差异,结论会更令人信服。

原始出处:

Yang Won Min, et al. Long-term survival after surgical resection for huge HCC: comparison with TACE after propensity score matching.Journal of Gastroenterology and Hepatology 10.1111/jgh.12504

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033669, encodeId=8fbd20336697e, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Oct 23 10:27:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863221, encodeId=74821863221ed, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Aug 19 10:27:00 CST 2014, time=2014-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978379, encodeId=456119e83792f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 11 08:27:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655690, encodeId=13651655690ce, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Aug 16 01:27:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429399, encodeId=8747142939948, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Thu Jan 16 03:27:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6813, encodeId=b7af68131e, content=MedSci评论值得看, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=8.35.201.33, createdTime=Tue Jan 14 13:55:00 CST 2014, time=2014-01-14, status=1, ipAttribution=)]
    2014-10-23 grace5700
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033669, encodeId=8fbd20336697e, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Oct 23 10:27:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863221, encodeId=74821863221ed, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Aug 19 10:27:00 CST 2014, time=2014-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978379, encodeId=456119e83792f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 11 08:27:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655690, encodeId=13651655690ce, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Aug 16 01:27:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429399, encodeId=8747142939948, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Thu Jan 16 03:27:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6813, encodeId=b7af68131e, content=MedSci评论值得看, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=8.35.201.33, createdTime=Tue Jan 14 13:55:00 CST 2014, time=2014-01-14, status=1, ipAttribution=)]
    2014-08-19 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033669, encodeId=8fbd20336697e, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Oct 23 10:27:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863221, encodeId=74821863221ed, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Aug 19 10:27:00 CST 2014, time=2014-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978379, encodeId=456119e83792f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 11 08:27:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655690, encodeId=13651655690ce, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Aug 16 01:27:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429399, encodeId=8747142939948, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Thu Jan 16 03:27:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6813, encodeId=b7af68131e, content=MedSci评论值得看, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=8.35.201.33, createdTime=Tue Jan 14 13:55:00 CST 2014, time=2014-01-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033669, encodeId=8fbd20336697e, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Oct 23 10:27:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863221, encodeId=74821863221ed, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Aug 19 10:27:00 CST 2014, time=2014-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978379, encodeId=456119e83792f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 11 08:27:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655690, encodeId=13651655690ce, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Aug 16 01:27:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429399, encodeId=8747142939948, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Thu Jan 16 03:27:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6813, encodeId=b7af68131e, content=MedSci评论值得看, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=8.35.201.33, createdTime=Tue Jan 14 13:55:00 CST 2014, time=2014-01-14, status=1, ipAttribution=)]
    2014-08-16 shanyongle
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033669, encodeId=8fbd20336697e, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Oct 23 10:27:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863221, encodeId=74821863221ed, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Aug 19 10:27:00 CST 2014, time=2014-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978379, encodeId=456119e83792f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 11 08:27:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655690, encodeId=13651655690ce, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Aug 16 01:27:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429399, encodeId=8747142939948, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Thu Jan 16 03:27:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6813, encodeId=b7af68131e, content=MedSci评论值得看, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=8.35.201.33, createdTime=Tue Jan 14 13:55:00 CST 2014, time=2014-01-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033669, encodeId=8fbd20336697e, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Oct 23 10:27:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863221, encodeId=74821863221ed, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Aug 19 10:27:00 CST 2014, time=2014-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978379, encodeId=456119e83792f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 11 08:27:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655690, encodeId=13651655690ce, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Aug 16 01:27:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429399, encodeId=8747142939948, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Thu Jan 16 03:27:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6813, encodeId=b7af68131e, content=MedSci评论值得看, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=8.35.201.33, createdTime=Tue Jan 14 13:55:00 CST 2014, time=2014-01-14, status=1, ipAttribution=)]
    2014-01-14 8.35.201.33

    MedSci评论值得看

    0

相关资讯

Gut:HBV血清标志物的自发清除是肝癌风险降低的预测因素

研究要点:1.在长期随访测量一系列HBV血清标志物的研究中,HBV DNA的血清清除对于显著降低肝癌风险是至关重要的。2.HBsAg血清清除对于确保HBV完全免疫清除是必要的。3.HBeAg的血清清除并非如之前研究的一样重要,因为患者血清清除HBeAg后仍有血清HBV DNA高水平。先前研究中观察到肝癌风险降低与HBeAg的血清清除存在相关可能是由于它与随后血清HBV-DNA的清除相关联,而不

Ann Surg Oncol:AFP分层有利于预测乙肝相关肝癌预后

研究要点 1.手术前的AFP检测是乙肝相关性肝癌切除术预后的预测指标。 2.将AFP分层和纤维化分层相结合就可以建立预测HCC预后的模型。 3.在现行的诊断标准下,即使AFP处于正常范围,不同的AFP也会影响HBV相关的肝癌的疾病进展和预后。 甲胎蛋白(AFP)水平与乙肝相关性肝细胞肝癌有关。虽然血浆AFP是影响病人生存率的指标之一,但最理想的临界值是多少还未知。来自美国的研究人员

Hepatology:肝癌形成分子调控机制获发现

来自第二军医大学的研究人员在新研究中证实,miR-370/Lin28A /NF-κB调控环路失常促进了肝癌形成。这一研究发现在线发表在国际著名肝脏疾病杂志Hepatology(最新影响因子12.003)上。

第二军医大学长征医院消化内科的谢渭芬(Wei-Fen Xie)教授是这篇论文的通讯作者。主要研究方向为慢性肝病的诊治。对脂肪肝、肝硬化等慢性肝病、胆道和胰腺疾病、胃肠疾病等消化道疾病的诊治积累了较丰富的经验。擅长胃镜、十二指肠镜、小肠镜等内镜诊断和治疗。2009年入选教育部“***奖励计划”特聘教授。先后发表SCI收录论著40余篇。

在世界范围内,原发性肝癌是第五大类常见的恶性肿瘤,其致死率在肿瘤相关疾病中排名第三,仅次于

Cancer Cell:NCOA5基因缺陷可能导致肝细胞癌、葡萄糖耐受不良

来自密歇根州立大学和南方医科大学的研究人员发现,一种遗传缺陷可以触发男性形成最常见的一种肝癌类型和糖尿病。这项研究在线发表于12月9日的《癌细胞》(Cancer Cell)杂志上。 南方医科大学南方医院罗荣城(Rongcheng Luo)教授和密歇根州立大学医学院生理学副教授肖华(Hua Xiao,音译)是这篇论文的共同通讯作者。罗荣城教授长期从事临床非常肿瘤学医教研

Hepatology:肝癌RRM2B下调与肝内转移呈负相关

来自上海交通大学医学院、浙江大学等处的研究人员在肝癌中证实,RRM2B通过Egr-1介导的PTEN/Akt1信号通路抑制了细胞迁移和扩散。这一研究成果已被国际著名肝脏疾病杂志Hepatology(最新影响因子12.003)接收并在线发表。 文章的通讯作者是上海交通大学医学院的李锦军(Jinjun Li )教授,其主要从事肝癌干细胞、肿瘤转移的分子机制研究。自2001年

Hepatology:香港中文大学Vincent WS Wong等发现AFP为诊断恩替卡韦治疗慢乙肝患者发生肝癌的特异性肿瘤标记物

研究要点:1.在诊断为肝癌的前6个月时甲胎蛋白开始升高。2.受试者工作特征曲线在患者诊断为肝癌时达到最高点,并在诊断前的3个月和6个月保持较高水平。3.0个月时(诊断为肝癌时),常规甲胎蛋白临界值(20μg/l)诊断肝癌的敏感性和特异性分别为38.6% 和98.9%。4.0个月时(诊断为肝癌时),较低甲胎蛋白水平临界值(6μg/l)诊断肝癌的灵敏度提高至80.7%,但特异性下降至80.4%。α-甲